Nanotech imaging, molecular fingerprints and signatures hold promise ...( e diagnosed in earlier stages of the di...),Health

e diagnosed in earlier stages of the disease. However, fewer women are diagnosed before ovarian cancer has advanced beyond stage one because the disease remains without obvious symptoms until late stage. Simple, specific and sensitive biomarker diagnostic assays that develop from mass spectrometric analysis of blood-borne proteomic arrays will help diagnose early stage development of ovarian cancer, Mehta said.

The albumin-binding biomarkers indicative of ovarian cancer were discovered by researchers from the National Cancer Institute of the NIH, the Center for Biologics Evaluation and Research at the FDA, the Howard Hughes Medical Institute, the Tufts University School of Medicine.

'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Association for Cancer Research
28-Mar-2004

Page: 1 2 3 4 5
Related medicine news :

1. Nanotech control device developed
2. 3D neutron-based medical imaging, 4D lung scans, and hitting a moving tumor
3. Ultrasound-guided liposomes boost imaging, target drug/gene therapy
4. Mayo Clinic researchers report success in new molecular breast imaging technique
5. New molecular classification of breast cancer predicts response to chemotherapy
6. New tool reveals molecular signature of cancer and HIV
7. Researchers monitor progression of Parkinsons disease by studying molecular changes in brain
8. Stanford scientists help bring study of smallpox virus into molecular age
9. Tiny molecular motors shed light on cell function, say Stanford researchers
10. Improved molecular beacons show promise for cancer detection, rapid viral diagnosis
11. New study provides molecular-level understanding of common anti-malarial drugs